Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC

Genprex, Inc.

REQORSA overexpressed TUSC2 tumor suppressor gene in ALK-EML4+ NSCLC cell lines and patient derived organoids.
Treatment induced apoptosis in ALK+ cells, including those resistant to alectinib; combination with alectinib further increased apoptosis.
In mouse xenograft model, REQORSA + alectinib improved survival vs control, suggesting potential for future clinical trial.
Data presented at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.